Supplemental Figures Legend from Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Thomas Van Looy(KU Leuven), Patrick Schöffski(KU Leuven), Haifu Li(Brigham and Women's Hospital), Ulla Vanleeuw(KU Leuven), Jasmien Wellens(Brigham and Women's Hospital), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Giuseppe Floris(KU Leuven), Raf Sciot(KU Leuven), Paul W. Manley(Auckland City Hospital), Jonathan A. Fletcher(Harvard University), Maria Dêbiec‐Rychter(Center for Human Genetics)
Cited by 0
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2016|766
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716